Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B M17YTmFxd3C2b4Ppd{BCe3OjeR?= MkjmNgKBmzYEoN88US=> Mkj5OFghcA>? M{DzPYlvcGmkaYTzJINmdGxiZ4Lve5Rp NHO5UY0zPjN{OU[wPC=>
PLC/PRF/5  M3;5SGFxd3C2b4Ppd{BCe3OjeR?= NGHESGQy6oDVNdMg{txO Mkm1OFghcA>? MnXubY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3Lrd|I3OzJ7NkC4
HepG2  NYLFXVJSSXCxcITvd4l{KEG|c3H5 M2DEelHjiJN3wrFOwG0> M3u1O|Q5KGh? NYPwZWtpcW6qaXLpeJMh[2WubDDndo94fGh? NUDpSm92OjZ|Mkm2NFg>
HEK293 NV;BSZRzTnWwY4Tpc44hSXO|YYm= MoXXNE426oDLzszN M1riZ|IwPC94IHi= NV;SO21oemWmdXPld{BIWlB5ODDlfJBz\XO|aX;u NXfzfXZuOjV6NUiwN|I>
GEO NIX0TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j5T|AvODFvMkCg{txO MV65OkBp M{DRUWROW09? MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWSyOVg{QDN7MR?=
SW48 Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOwMlAyNTJyIN88US=> MXK5OkBp NVjpdm9LTE2VTx?= NFLqenNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2rtfFI2QDN6M{mx
HT29 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnGNE4xOS1{MDFOwG0> NYHJcoFDQTZiaB?= M3rDc2ROW09? NWf6dJJKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXmyOVg{QDN7MR?=
SW480 NUT0XGZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHFbJkxNjBzLUKwJO69VQ>? NFm2cII6PiCq NEfnc4pFVVOR NHnH[IRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{\tT|I2QDN6M{mx
SW620 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3PNYsxNjBzLUKwJO69VQ>? NF\keHY6PiCq NUf0e2JVTE2VTx?= NUH1RY1qcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFHENJMzPTh|OEO5NS=>
HCT116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvSoYxNjBzLUKwJO69VQ>? M3;pc|k3KGh? NH7URW5FVVOR MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWe1U2RHOjV6M{izPVE>
LOVO M4C2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXmR4ZLOC5yMT2yNEDPxE1? NYHzb5lGQTZiaB?= M{XXfGROW09? NWX0fIZbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mnf1NlU5Ozh|OUG=
HCT150 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYewMlAyNTJyIN88US=> MkPhPVYhcA>? NYT2RotxTE2VTx?= NFrOSHZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4PBbFI2QDN6M{mx
SW48-CR M4ryXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3yU3JNOC5yMT2yNEDPxE1? NXjyZllUQTZiaB?= M3SyemROW09? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYOyOVg{QDN7MR?=
GEO-CR MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorINE4xOS1{MDFOwG0> Ml\HPVYhcA>? MVXEUXNQ MmHsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFPZfXUzPTh|OEO5NS=>
KB-31 M3zoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2RoZTUUN3ME21MlXDuTBwMzDuUS=> M17reVI2PzV|M{[x
KB-G2 M1Hwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnQXGVKSzVyPUmuNeKyOC5zIH7N NE[wZpUzPTd3M{O2NS=>
LLC-PK1 M2f6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HJTmlEPTB;NEKuNOKyOy5{IH7N MVyyOVc2OzN4MR?=
LLC-PK1/MRP2 NXHJdpJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTh{LkVCtVIvPyCwTR?= MYGyOVc2OzN4MR?=
HEK293 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULoe4RbUUN3ME2xNU4xyrFzLkKgcm0> MU[yOVc2OzN4MR?=
HEK293/OATP1B1 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF31dVRKSzVyPU[uNuKyOC5|IH7N MlTiNlU4PTN|NkG=
HROC18 NXjKflk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXiU2VKSzVyPUGuN{DPxE1? MUmyOVMxQTlzNB?=
HROC24 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRwNjFOwG0> NWf4eWJZOjV|MEm5NVQ>
HROC43 M4faN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvETWM2OD13LkOg{txO MkXoNlU{ODl7MUS=
HROC46 M3vOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PsNGlEPTB;Mj60JO69VQ>? NF2wTnEzPTNyOUmxOC=>
RJ345 NEf4cWpHfW6ldHnvckBCe3OjeR?= M2TQ[VAvPS93IN88US=> NFi5[JIzPCCq M1LOO2ROW09? Mn3pbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u MXqyOVI2Ozl7NB?=
RJ348 MkXsSpVv[3Srb36gRZN{[Xl? NHj1VmwxNjVxNTFOwG0> M4XNT|I1KGh? NWfOSYE2TE2VTx?= Mn;EbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u M1\1TlI2OjV|OUm0
MCF-7 MXXGeY5kfGmxbjDBd5NigQ>? MVmwMlUwPSEQvF2= NUHObZBtOjRiaB?= MX;EUXNQ NFLEVINqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> M3zkUVI2OjV|OUm0
MDA-MB-231 MVzGeY5kfGmxbjDBd5NigQ>? NIjCT2wxNjVxNTFOwG0> MVeyOEBp Ml\SSG1UVw>? Mn3sbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u NFzuO2YzPTJ3M{m5OC=>
HT15 NF\TXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXqW24yNTJyIN88US=> MnrWOFghcA>? MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGfyfGIzPTB5MUCxPC=>
DLD1 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXPUm4yNTJyIN88US=> MljOOFghcA>? MnzybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXP3WVJqOjVyN{GwNVg>
HT-29 NFyyZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xMVIxKM7:TR?= M{nxe|Q5KGh? NX3hflZYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV:yOVA4OTBzOB?=
Hct-116 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WzS|EuOjBizszN MmTXOFghcA>? MoX5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlzwNlUxPzFyMUi=
HT15 MV3BdI9xfG:|aYOgRZN{[Xl? MXWxMVExKM7:TR?= MUC0PEBp NHzDVpRqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NX7QXGZTOjVyN{GwNVg>
DLD1 M3jWfmFxd3C2b4Ppd{BCe3OjeR?= NWnkU5dPOS1zMDFOwG0> NUL3[4hnPDhiaB?= NHvRNJNqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2fKT|I2ODdzMEG4
HT-29 NInJbHhCeG:ydH;zbZMhSXO|YYm= NVW0TnA{OS1zMDFOwG0> Ml:zOFghcA>? MWPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV:yOVA4OTBzOB?=
Hct-116 NFjNOmpCeG:ydH;zbZMhSXO|YYm= M3nDUFEuOTBizszN M3mxcVQ5KGh? NUT0PXhVcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NF\kR5AzPTB5MUCxPC=>
GBM5 NE\mXW9CeG:ydH;zbZMhSXO|YYm= NYTKbWY1OC534pETNU4x6oDLzszN Ml7sNlQhcA>? NITVeGpFVVOR M4DlXIlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> M2HCV|I1QTFzMkG1
GBM6 NUTOSXp2SXCxcITvd4l{KEG|c3H5 NX;DbWMzOC534pETNU4x6oDLzszN NV\OdodKOjRiaB?= M{XwU2ROW09? NEfEe2ZqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> M33TdFI1QTFzMkG1
GBM12 NFLCeXlCeG:ydH;zbZMhSXO|YYm= NEDSSIIxNjYkgKOxMlDjiIoQvF2= NXvTOIRsOjRiaB?= NYjTcXJkTE2VTx?= MnvCbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo MUKyOFkyOTJzNR?=
GBM14  NIPVV21CeG:ydH;zbZMhSXO|YYm= M{jVUlAvPeLCk{GuNQKBkc7:TR?= NXf2XpRCOjRiaB?= NYPrPGNFTE2VTx?= MmXRbY51\XKjY4TzJJdqfGhibHHwZZRqdmmkIITvJIlv\HWlZTDj[YxtKGSnYYTo NX7O[5ZFOjR7MUGyNVU>
Hep3B NILzR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjWRlEy6oDVMj61xsDPxE1? MnqxNlQwPDhxN{KgbC=> M{\QZolvcGmkaYTzJINmdGxiZ4Lve5Rp MXKyOFg5PTh7MB?=
PLC/PRF/5  MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf6NgKBmzJwNdMg{txO MUiyOE81QC95MjDo MlvjbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NEXDUlEzPDh6NUi5NC=>
HepG2  NHTzUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m5c|HjiJN{LkZCpO69VQ>? MUKyOE81QC95MjDo NV61[5Y4cW6qaXLpeJMh[2WubDDndo94fGh? M3\lUlI1QDh3OEmw
HCT116  MXzGeY5kfGmxbjDBd5NigQ>? MYCxNE8zOC92MDFOwG0> NXr5UZFMOjRiaB?= MWLpcoR2[2W|IGDVUWEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MVKyOFc3OzZzMR?=
Lim2405 NYfSU4d4TnWwY4Tpc44hSXO|YYm= MorFOFAh|ryP MY[yOEBp NWL5dGNicW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NF;B[FMzPDd4M{[xNS=>
LoVo MlPlSpVv[3Srb36gRZN{[Xl? NFH4S3U1OCEQvF2= NXfGXXQzOjRiaB?= NETvPXlqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MWKyOFc3OzZzMR?=
Lim1215 MW\GeY5kfGmxbjDBd5NigQ>? M2nvRlQxKM7:TR?= NIPzPXozPCCq NIPY[FFqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MYCyOFc3OzZzMR?=
SW48 M3jscWZ2dmO2aX;uJGF{e2G7 NHOwZ4w1OCEQvF2= MVeyOEBp M{j2UYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NGLjbYIzPDd4M{[xNS=>
RKO  NYDoSYtvTnWwY4Tpc44hSXO|YYm= M2HCZlQxKM7:TR?= NXjmdXQ{OjRiaB?= MWPpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NGS1XWkzPDd4M{[xNS=>
SW837 M3X0O2Z2dmO2aX;uJGF{e2G7 M4OxV|QxKM7:TR?= NUP4bJhkOjRiaB?= M{jXW4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M4jkNVI1PzZ|NkGx
SW1463 MYXGeY5kfGmxbjDBd5NigQ>? MWW0NEDPxE1? Ml\BNlQhcA>? MlnFbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NHK3XWszPDd4M{[xNS=>
SW480 NIf1XWpHfW6ldHnvckBCe3OjeR?= MV:0NEDPxE1? MVuyOEBp MVzpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MnvrNlQ4PjN4MUG=
Vaco432 NYfndll5TnWwY4Tpc44hSXO|YYm= NX7VS4RLPDBizszN MX6yOEBp NVrZ[5NtcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NVTrZlhDOjR5NkO2NVE>
Vaco400 NIH5[GhHfW6ldHnvckBCe3OjeR?= M4PmNFQxKM7:TR?= NFy1W5MzPCCq MX\pcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M4iyeVI1PzZ|NkGx
DLD1 NYr3OHh2TnWwY4Tpc44hSXO|YYm= NWDlPI5CPDBizszN NU\sUnJYOjRiaB?= NIjUPYZqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NHfnWJUzPDd4M{[xNS=>
HT29  M4HNVmZ2dmO2aX;uJGF{e2G7 MlzJOFAh|ryP NYq1e2x2OjRiaB?= NFvhV5NqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MoHPNlQ4PjN4MUG=
PLC/PRF/5  Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HqcFHjiJN3wsXN MUiyOE81QC95MjDo NFLafpZqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M4XI[FI{OTZ7MUS4
HepG2 M2L0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojaNgKBmzYEtV2= MmLpNlQwPDhxN{KgbC=> NYrEZVBJcW6qaXLpeJMh[2WubDDndo94fGh? NVf0TZp{OjNzNkmxOFg>
Hep3B  NVjkVnJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELJRW4y6oDVNdM1US=> NHHTbHMzPC92OD:3NkBp NWH0fmlWcW6qaXLpeJMh[2WubDDndo94fGh? MmnZNlMyPjlzNEi=

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID